Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11294	Companies
250971	Keywords
179884	Articles
136841	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 1 year 1 month ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 1 year 1 month ago

Biophytis obtient un financement public au Brésil pour l’essai de Phase 2 dans l’obésité et signe des accords avec des centres cliniques locaux de premier plan
Biophytis obtient un financement public et signe des accords pour l'essai de Phase 2 dans l'obésité au Brésil, renforçant ainsi son programme et sa valeur pour les investisseurs

Biophytis Brésil Phase 2 Obésité Financement Public
BRIEF

published on 09/11/2025 at 07:05, 1 year 1 month ago

Biophytis Lance un Essai de Phase 3 sur la Sarcopénie avec BIO101

Biophytis Essai Clinique Sarcopénie BIO101 Europe Et Asie
BRIEF

published on 09/11/2025 at 07:05, 1 year 1 month ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 1 year 1 month ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis annonce sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et en Asie, ciblant un marché médical important et non satisfait

Biophytis Europe Asie Sarcopénie Phase 3
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 1 year 1 month ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
PRESS RELEASE

published on 09/11/2025 at 06:59, 1 year 1 month ago

Biophytis dévoile sa stratégie d’essai de phase 3 dans la sarcopénie avec BIO101 en Europe et en Asie
Biophytis présente sa stratégie d'essai de phase 3 pour la sarcopénie avec BIO101 en Europe et Asie, visant à devenir pionnier dans ce domaine thérapeutique en croissance rapide

Biophytis Essai Clinique Sarcopénie Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 1 year 2 months ago

Biophytis obtient l'approbation de l'EMA pour une étude clinique phase 2 sur l'obésité

Biophytis Essai Clinique Phase 2 Obésité EMA
BRIEF

published on 09/03/2025 at 07:05, 1 year 2 months ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 1 year 2 months ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone

Accesswire

Published on 11/06/2026 at 22:15, 2 days 7 hours ago

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 16 hours ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 17 hours ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 17 hours ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 2 days 19 hours ago

Mongolia Tax Audit

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 01:55, 3 hours 59 minutes ago

EQS-Adhoc: NEXTDC Limited: Response to Statement by Goodman Group & Digital Realty
Published on 11/08/2026 at 12:10, 17 hours 44 minutes ago

GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/08/2026 at 10:15, 19 hours 39 minutes ago

2026 China International Intelligent Communication Forum Held in Wuxi
Published on 11/07/2026 at 13:35, 1 day 16 hours ago

Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 2 days 9 hours ago

African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing

Les Echos

Published on 11/06/2026 at 19:06, 2 days 10 hours ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 2 days 10 hours ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 2 days 10 hours ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 2 days 10 hours ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 18:00, 2 days 11 hours ago

ICADE - CP - Notation crédit S&P

View all LES ECHOS COMFI WIRE